General
Preferred name
Ibandronate
Synonyms
IBANDRONIC ACID ()
IBANDRONATE SODIUM ()
BM 21.0955 ()
IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE ()
Boniva ()
Bondronat ()
Ibandronate sodium salt ()
Bonviva ()
Bondenza sodium monohydrate ()
BM-21.0955 ()
Ibandronate sodium monohydrate ()
BM-210955 ()
RPR-102289A ()
Ibandronate sodium ()
ibandronate, Lanco Biosciences ()
Ibandronate (Sodium Monohydrate) ()
Ibandronate (Sodium) ()
Ibandronate sodium hydrate ()
BM-21.0955, BM-210955, RPR-102289A ()
NSC-759815 ()
BM 21.0955 NA H20 ()
Bondenza (previously ibandronic acid roche) ()
Ibandronic sodium monohydrate ()
Ibandronic acid accord ()
Destara ()
Ibandronate sodium component of dp-r206 ibandronate ()
Ibandronic acid sodium salt monohydrate ()
Sodium ibandronate monohydrate ()
Iasibon ()
Ibandronic acid sandoz ()
Ibandronic acid teva ()
Ibandronic acid sodium salt ()
Ibandronate monosodium monohydrate ()
Acido ibandronico ()
Bondenza ()
NSC-722623 ()
Acide ibandronique ()
Ibandronate (sodium hydrate) ()
P&D ID
PD010067
CAS
114084-78-5
138844-81-2
138926-19-9
Tags
available
drug
Approved by
EMA
FDA
First approval
1996
Drug indication
Postmenopausal osteoporosis
Osteoporosis
Drug Status
approved
investigational
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
PRICE
38
DESCRIPTION
Ibandronic acid is a potent bisphosphonate drug.
(GtoPdb)
PRICE
29
DESCRIPTION
Ibandronate sodium hydrate is a bisphosphonate. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate sodium hydrate induces apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl pyrophosphate synthase.
(Enamine Bioactive Compounds)
DESCRIPTION
Ibandronate sodium (Boniva) is a synthetic nitrogen-containing bisphosphonate, used for the treatment of osteoporosis.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Ibandronate sodium monohydrate (BM-210955) is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Ibandronic acid (Bonviva) is a third-generation amino-bisphosphonate with anti-resorptive and anti-hypercalcemic activities.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Ibandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Farnesyl diphosphate synthase inhibitor; inhibits bone resorption.
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
3
Compound Sets
35
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LINCS compound set
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
174
Molecular Weight
319.09
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
5
Rotatable Bonds
9
Ring Count
0
Aromatic Ring Count
0
cLogP
0.5
TPSA
138.53
Fraction CSP3
1.0
Chiral centers
0.0
Largest ring
0.0
QED
0.31
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
Farnesyl diphosphate synthase
Target
Farnesyl pyrophosphate synthase
HAP
FPPS
Apoptosis
FDPS
MOA
HBV inhibitor
bone resorption inhibitor
Indication
osteoporosis
ATC
M05BA06
Pathway
Metabolism
Microbiology/virology
Therapeutic Class
Bone Density Conservation Agents
Source data

